Jonah Comstock is the Editor in Chief at pharmaphorum. He specializes in health tech journalism, covering a range of topics including digital health, telehealth, and the intersection of healthcare technology with pharmaceuticals and legal affairs. Jonah's insights and expertise are regularly featured in pharmaphorum.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .
Looking back to May, the pharma and biotech sector saw a steady stream of senior leadership changes this month, spanning big pharma, emerging biotech, and research organisations.
As the US relaxes an export ban on Anthropic's advanced AI tools, the company formally launched Claude Science, an AI 'workbench' for researchers involved in drug discovery.
The digital, supplier, CRO, and medtech services sectors continued to see a steady flow of leadership changes during the month of May, with companies reinforcing capabilities across clinical strategy, commercialisation, and technology. A cluster of CEO appointments stood out at the top of the list.
When it comes to global pharma pricing and market access, this moment is one of unprecedented change.
A federal judge in the US has sided with Amgen in a dispute over a price cap imposed by the state of Colorado on blockbuster immunology drug Enbrel.
By: Jonah Comstock
The agency, consultancy, and investor segments saw a wave of senior-level appointments across April and May, as organisations invested in technology leadership, strategic advisory, and specialist communications expertise.
From chair roles to new board and advisory appointments, the latest moves reflect a focus on experience in commercialisation, corporate governance, and therapeutic development.
Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq as it advances its spin on CRISPR-based therapeutics.
A phase 1/2 trial in the rare disease light chain amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.
The oncology space today is an array of different innovative mechanisms of action, and companies of all sizes are trying to keep pace with the cutting edge of the space.
